NCT02363933View on ClinicalTrials.gov

Perampanel in Seizure Patients With Primary Glial Brain Tumors

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 7, 2015

Primary Completion Date

March 14, 2017

Study Completion Date

April 10, 2017

Conditions
Brain Tumor, Primary
Interventions
DRUG

Perampanel

Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures

Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER